<DOC>
	<DOCNO>NCT00856544</DOCNO>
	<brief_summary>This Phase 3 study intend provide evidence CP-690,550 dose 5 mg BID 10 mg BID safe effective use combination variety traditional disease modify antirheumatic drug adult patient rheumatoid arthritis . It intend confirm benefit CP-690,550 improve sign symptom physical function observe Phase 2 rheumatoid arthritis study .</brief_summary>
	<brief_title>A Study Comparing 2 Doses Of CP-690,550 Vs . Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient diagnosis Rheumatoid Arthritis base American College Rheumatology ( ACR ) 1987 Revised Criteria . The patient active disease define &gt; =4 tender painful joint motion &gt; = 4 joint swell ; either erythrocyte sedimentation rate ( ESR ) &gt; 28 mm Creactive protein ( CRP ) concentration &gt; 7 mg/dL . Patient inadequate response least one disease modify antirheumatic drug ( traditional biologic ) due lack efficacy toxicity . Patient must remain least one background traditional disease modify antirheumatic drug . No evidence inadequately treat latent active infection Mycobacterium tuberculosis . Blood dyscrasias include confirm : Hemoglobin &lt; 9 g/dL Hematocrit &lt; 30 % ; White blood cell count &lt; 3.0 x 109/L ; Absolute neutrophil count &lt; 1.2 x 109/L ; Platelet count &lt; 100 x 109/L . History rheumatic autoimmune disease Sjogren 's syndrome . No malignancy history malignancy . History infection require hospitalization , parenteral antimicrobial therapy , otherwise judge clinically significant investigator , within 6 month prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>